SCHEMBL4926110

SCHEMBL4926110

CCCCCCCC=C(C(C)=O)C(=O)OCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 1/20 0.56
EP300 Q09472 1/20 0.55
FAAH O00519 2/20 0.53
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP2D6 P10635 1/20 0.42
TSHR P16473 2/20 0.40
GAA P10253 1/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PRKCA P17252 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11717795 1.00 GLO1 (0.56) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL4926108 1.00 GLO1 (0.56) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL11726309 1.00 GLO1 (0.56) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL11717792 1.00 GLO1 (0.56) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL11726317 1.00 GLO1 (0.56) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL12693568 1.00 GLO1 (0.56) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL10788834 0.91 EP300 (0.60) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL11439397 0.91 EP300 (0.60) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL20771517 0.91 EP300 (0.60) GLO1EP300FAAHNPSR1ALDH1A1
SCHEMBL4914440 0.91 EP300 (0.60) GLO1EP300FAAHNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080305066-A1 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour GIVAUDAN SA (CH) 2008-12-11 US claimed
EP-1838278-A1 2-C-SUBSTITUTED PROPANE-1,3-DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR Givaudan SA (CH) 2007-10-03 EP claimed
WO-2006076821-A1 2 -C-SUBSTITUTED PROPANE-1, 3 -DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR GIVAUDAN SA (CH) 2006-07-27 WO claimed
US-20240041752-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2024-02-08 US disclosed
EP-4288022-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2023-12-13 EP disclosed
WO-2022167123-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2022-08-11 WO disclosed
EP-4039244-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2022-08-10 EP disclosed
US-20080305066-A1 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour GIVAUDAN SA (CH) 2008-12-11 US disclosed
EP-1838278-A1 2-C-SUBSTITUTED PROPANE-1,3-DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR Givaudan SA (CH) 2007-10-03 EP disclosed
WO-2006076821-A1 2 -C-SUBSTITUTED PROPANE-1, 3 -DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR GIVAUDAN SA (CH) 2006-07-27 WO disclosed
US-4025537-A Preparation of 3-carboalkoxy or 3-alkanoyl furans KRETCHMER RICHARD ALLAN 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305066-A1 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour TYR, MAL2, ACMSD GLO1 171/4885EP300 2098/4885FAAH 1305/4885
US-20240041752-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AOX1, TYR, OCIAD1 GLO1 36/4885EP300 2974/4885FAAH 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.